PRESAMINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Apr 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRESAMINE is an oral small-molecule tablet approved in 1959 by Sanofi under NDA status. The mechanism of action and specific indications are not documented in available records, limiting characterization of its therapeutic role.
LOE Approaching
As PRESAMINE approaches loss of exclusivity with no documented current sales data, commercial teams are likely in transition or sunset mode with minimal growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRESAMINE offers minimal career growth; opportunities are limited to managing a mature, LOE-approaching asset or transitioning to next-generation products. This is not a launch or growth assignment and carries reputational risk of association with a declining brand.
Supply Chain / OperationsRegulatory Affairs
Worked on PRESAMINE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.